Literature DB >> 29664296

PPARα Mediates the Hepatoprotective Effects of Nutmeg.

Xiao-Nan Yang1, Xue-Mei Liu1,2, Jian-He Fang3, Xu Zhu1, Xiu-Wei Yang4, Xue-Rong Xiao1, Jian-Feng Huang1, Frank J Gonzalez5, Fei Li1,6.   

Abstract

Nutmeg is a Traditional Chinese Medicine used to treat gastrointestinal diseases. Some reports have indicated that nutmeg has hepatoprotective activity. In this study, a thioacetamide (TAA)-induced acute liver injury model in mice was used to explore the mechanism of the protective effects of nutmeg extract (NME), including its major bioactive component myrislignan. The results indicated that NME could effectively protect TAA-induced liver damage as assessed by recovery of increased serumtransaminases, decrease in hepatic oxidative stress, and lower hepatic inflammation. Metabolomics analysis further revealed that treatment with NME led to the recovery of a series of lipids including lysophosphatidylcholines that were decreased and a lowering of acylcarnitines that were increased in mouse plasma and liver after TAA exposure. Gene expression analysis demonstrated that the hepatoprotective effect of NME was achieved by modulation of the peroxisome proliferator-activated receptor alpha (PPARα) as well as the decrease in oxidative stress. NME could not protect from TAA-induced liver injury in Ppara-null mice, suggesting that its protective effect was dependent on PPARα. Myrislignan, a representative neolignan in nutmeg, showed potent protective activity against TAA-induced liver toxicity. These data demonstrate that nutmeg alleviates TAA-induced liver injury through the modulation of PPARα and that the lignan compounds in nutmeg such as myrislignan partly contributed to this action.

Entities:  

Keywords:  PPARα; hepatoprotective activity; metabolomics; myrislignan; nutmeg

Mesh:

Substances:

Year:  2018        PMID: 29664296      PMCID: PMC6628927          DOI: 10.1021/acs.jproteome.7b00901

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  7 in total

1.  Celastrol ameliorates acute liver injury through modulation of PPARα.

Authors:  Qi Zhao; Ping Tang; Ting Zhang; Jian-Feng Huang; Xue-Rong Xiao; Wei-Feng Zhu; Frank J Gonzalez; Fei Li
Journal:  Biochem Pharmacol       Date:  2020-05-26       Impact factor: 5.858

2.  Metabolic Activation of Elemicin Leads to the Inhibition of Stearoyl-CoA Desaturase 1.

Authors:  Xiao-Nan Yang; Yi-Kun Wang; Xu Zhu; Xue-Rong Xiao; Man-Yun Dai; Ting Zhang; Yan Qu; Xiu-Wei Yang; Hong-Bo Qin; Frank J Gonzalez; Fei Li
Journal:  Chem Res Toxicol       Date:  2019-09-10       Impact factor: 3.739

3.  Myristica fragrans Extract Regulates Gut Microbes and Metabolites to Attenuate Hepatic Inflammation and Lipid Metabolism Disorders via the AhR-FAS and NF-κB Signaling Pathways in Mice with Non-Alcoholic Fatty Liver Disease.

Authors:  Wenyu Zhao; Min Guo; Jun Feng; Zhennan Gu; Jianxin Zhao; Hao Zhang; Gang Wang; Wei Chen
Journal:  Nutrients       Date:  2022-04-19       Impact factor: 6.706

Review 4.  COVID-19, cytokines, inflammation, and spices: How are they related?

Authors:  Ajaikumar B Kunnumakkara; Varsha Rana; Dey Parama; Kishore Banik; Sosmitha Girisa; Sahu Henamayee; Krishan Kumar Thakur; Uma Dutta; Prachi Garodia; Subash C Gupta; Bharat B Aggarwal
Journal:  Life Sci       Date:  2021-02-16       Impact factor: 5.037

5.  Application of Metabolomics in the Study of Natural Products.

Authors:  Qi Zhao; Jia-Le Zhang; Fei Li
Journal:  Nat Prod Bioprospect       Date:  2018-06-29

Review 6.  Unravelling the Anticancer Mechanisms of Traditional Herbal Medicines with Metabolomics.

Authors:  Omolola R Oyenihi; Ayodeji B Oyenihi; Joseph O Erhabor; Motlalepula G Matsabisa; Oluwafemi O Oguntibeju
Journal:  Molecules       Date:  2021-10-29       Impact factor: 4.411

7.  Myrislignan Exhibits Activities Against Toxoplasma gondii RH Strain by Triggering Mitochondrial Dysfunction.

Authors:  Jili Zhang; Hongfei Si; Bing Li; Xuzheng Zhou; Jiyu Zhang
Journal:  Front Microbiol       Date:  2019-09-18       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.